TrialBMJ open2022

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.

Daniel J George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.